MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS

MiNK Therapeutics (NASDAQ:INKT) released its quarterly earnings data on Friday. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.20, Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK said its AGENT-797 iNKT platform continues to show encouraging signals across oncology and critical illness, including durable survival in refractory gastric cancer and immune modulation in ARDS and lung injury.
• The company initiated a randomized phase II ARDS trial of AGENT-797 versus placebo on top of standard of care, with a planned seamless phase II/III design and FDA discussions expected in the coming weeks.
• Management highlighted translational data showing the same donor-derived product can generate different immune responses depending on disease state, supporting a potential biomarker-driven approach for patient selection in ARDS.
• MiNK’s cash position of about $9.5 million at quarter-end, plus operational efficiencies and non-dilutive collaboration support, is expected to fund at least the next 12 months of operations, including the randomized trial launch.
• The company also expanded its pipeline and partnership strategy through a C-Further collaboration for a PRAME-targeted TCR-engineered iNKT program in pediatric cancers and said it will present additional data, including an ANKTIVA combination study, at upcoming medical meetings.

MiNK Therapeutics Trading Up 2.0%

Shares of NASDAQ:INKT traded up $0.21 on Friday, reaching $10.72. 36,280 shares of the company’s stock were exchanged, compared to its average volume of 207,695. The company has a fifty day moving average of $11.01 and a 200-day moving average of $11.61. MiNK Therapeutics has a twelve month low of $6.65 and a twelve month high of $76.00. The company has a market capitalization of $53.39 million, a price-to-earnings ratio of -3.61 and a beta of 0.47.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on INKT. Weiss Ratings lowered shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wall Street Zen upgraded shares of MiNK Therapeutics to a “sell” rating in a research note on Saturday, April 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research note on Wednesday, April 1st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MiNK Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $35.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC grew its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent quarter. 2.87% of the stock is currently owned by hedge funds and other institutional investors.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.